Literature DB >> 31673124

The global pipeline of cell therapies for cancer.

Jia Xin Yu, Vanessa M Hubbard-Lucey, Jun Tang.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31673124     DOI： 10.1038/d41573-019-00090-z

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  14 in total

Review 1.  Industrializing engineered autologous T cells as medicines for solid tumours.

Authors:  Cedrik M Britten; Aiman Shalabi; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2021-04-08       Impact factor: 84.694

Review 2.  Multipurposing CARs: Same engine, different vehicles.

Authors:  A K M Nawshad Hossian; Christopher S Hackett; Renier J Brentjens; Sarwish Rafiq
Journal:  Mol Ther       Date:  2022-02-11       Impact factor: 12.910

3.  A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy.

Authors:  Lupeng Ye; Jonathan J Park; Lei Peng; Quanjun Yang; Ryan D Chow; Matthew B Dong; Stanley Z Lam; Jianjian Guo; Erting Tang; Yueqi Zhang; Guangchuan Wang; Xiaoyun Dai; Yaying Du; Hyunu R Kim; Hanbing Cao; Youssef Errami; Paul Clark; Alexey Bersenev; Ruth R Montgomery; Sidi Chen
Journal:  Cell Metab       Date:  2022-03-10       Impact factor: 31.373

4.  The TNFSF Members APRIL and BAFF and Their Receptors TACI, BCMA, and BAFFR in Oncology, With a Special Focus in Breast Cancer.

Authors:  Marilena Kampa; George Notas; Efstathios N Stathopoulos; Andreas Tsapis; Elias Castanas
Journal:  Front Oncol       Date:  2020-06-16       Impact factor: 6.244

Review 5.  Recent Progress of Potentiating Immune Checkpoint Blockade with External Stimuli-an Industry Perspective.

Authors:  Jun Xu; Robert Saklatvala; Sachin Mittal; Smeet Deshmukh; Adam Procopio
Journal:  Adv Sci (Weinh)       Date:  2020-02-28       Impact factor: 16.806

6.  Synthetic promoters to induce immune-effectors into the tumor microenvironment.

Authors:  Roi Gazit; Angel Porgador; Yariv Greenshpan; Omri Sharabi; Aner Ottolenghi; Avishag Cahana; Kiran Kundu; Ksenia M Yegodayev; Moshe Elkabets
Journal:  Commun Biol       Date:  2021-01-29

Review 7.  The Application of Nanobody in CAR-T Therapy.

Authors:  Chaolemeng Bao; Quanli Gao; Lin-Lin Li; Lu Han; Bingxiang Zhang; Yijin Ding; Zongpei Song; Ruining Zhang; Jishuai Zhang; Xian-Hui Wu
Journal:  Biomolecules       Date:  2021-02-08

Review 8.  Investigating T Cell Immunity in Cancer: Achievements and Prospects.

Authors:  Zhen Zeng; Hui Yi Chew; Jazmina G Cruz; Graham R Leggatt; James W Wells
Journal:  Int J Mol Sci       Date:  2021-03-12       Impact factor: 5.923

9.  Acute Lymphoblastic Leukemia Relapse Limited to the Anterior Chamber of the Eye and Treated with Novel CAR T-Cell Therapy.

Authors:  Nir Gomel; Eliya Levinger; Ron Ram; Dror Limon; Zohar Habot-Wilner
Journal:  Case Rep Ophthalmol       Date:  2021-12-28

10.  Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity.

Authors:  John C Flickinger; Jagmohan Singh; Robert Carlson; Elinor Leong; Trevor R Baybutt; Joshua Barton; Ellen Caparosa; Amanda Pattison; Jeffrey A Rappaport; Jamin Roh; Tingting Zhan; Babar Bashir; Scott A Waldman; Adam E Snook
Journal:  J Immunother Cancer       Date:  2020-08       Impact factor: 12.469
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.